NYSEARCA:GERM Amplify Treatments, Testing and Advancements ETF (GERM) Price, Holdings, & News $19.89 +0.17 (+0.86%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$19.89▼$19.8950-Day Range$17.79▼$20.2052-Week Range$15.67▼$20.70Volume294 shsAverage Volume2,011 shsMarket Capitalization$10.94 millionAssets Under Management$9.87 millionDividend Yield0.70%Net Expense Ratio0.68% Stock AnalysisStock AnalysisChartHoldingsRatingsStock AnalysisChartHoldingsRatings Get Amplify Treatments, Testing and Advancements ETF alerts: Email Address About Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM)The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.Read More GERM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERM ETF News HeadlinesFebruary 11, 2024 | thestreet.comETFMG Treatments Testing and Advancements ETFDecember 28, 2023 | msn.comETFMG Treatments, Testing and Advancements ETF declares $0.0522 dividendJuly 27, 2024 | The Oxford Club (Ad)Alex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.August 25, 2023 | seekingalpha.comGERM ETFMG Treatments, Testing and Advancements ETFJune 23, 2023 | msn.comETFMG Treatments, Testing and Advancements ETF declares quarterly distribution of $0.0600April 25, 2023 | usatoday.comCutting-edge advances in cancer treatment are underway. Here are 3 that could change lives.April 11, 2023 | msn.comJP Morgan Maintains Moderna (MRNA) Neutral RecommendationMarch 24, 2023 | marketwatch.comLactose Intolerance Treatment Market Growth by 2031July 27, 2024 | The Oxford Club (Ad)Alex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.March 8, 2023 | marketwatch.comLatest "Blood Culture Test Market" Insights, Trends & Future Development Status Recorded During 2023-2028See More Headlines Receive GERM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplify Treatments, Testing and Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerAmplify Fund NameAmplify Treatments, Testing and Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:GERM Inception Date6/17/2020 Fund ManagerCharles Ragauss, Qiao Duan WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkPrime Treatments, Testing and Advancements Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings56 Fund Statistics Assets Under Management$9.87 million Average Daily Volume$0.00 Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorAmplify Investments LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest100 shs Miscellaneous Outstanding Shares550,000Beta1.08 Creation Unit50,000 Creation Fee$300.00 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Ad The Oxford ClubAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.Watch Alex's "Next Magnificent Seven" presentation now. Amplify Treatments, Testing and Advancements ETF ExpensesTypeGERMTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.68%0.57%0.54%0.51%0.51%Other Expenses0.00%0.57%0.50%0.59%0.54%Total Expense0.68%0.73%0.70%0.74%0.71%Fee Waiver0.00%-0.74%-0.54%-0.69%-0.59%Net Expense0.68%0.59%0.60%0.58%0.58% Amplify Treatments, Testing and Advancements ETF (GERM) Holdings & ExposureTop 10 GERM HoldingsAlnylam Pharmaceuticals(NASDAQ:ALNY)Holding Weight: 9.60%Laboratory Co. of America(NYSE:LH)Holding Weight: 6.40%Quest Diagnostics(NYSE:DGX)Holding Weight: 6.11%BioNTech(NASDAQ:BNTX)Holding Weight: 4.95%Vaxcyte(NASDAQ:PCVX)Holding Weight: 4.75%Moderna(NASDAQ:MRNA)Holding Weight: 4.63%Bio-Rad Laboratories(NYSE:BIO)Holding Weight: 4.33%Zai Lab(NASDAQ:ZLAB)Holding Weight: 4.06%Immunocore(NASDAQ:IMCR)Holding Weight: 3.75%QuidelOrtho(NASDAQ:QDEL)Holding Weight: 3.64%GERM Sector ExposureGERM Industry ExposureFull Holdings Details Similar ETFsB.A.D. EtfNYSEARCA:BADFirst Trust Alerian US NextGen Infrastructure ETFNYSEARCA:RBLDSmartETFs Smart Transportation & TechnologyETFNYSEARCA:MOTOHorizon Kinetics Blockchain Development ETFNYSEARCA:BCDFDirexion Daily Travel & Vacation Bull 2X SharesNYSEARCA:OOTO GERM ETF - Frequently Asked Questions How have GERM shares performed this year? Amplify Treatments, Testing and Advancements ETF's stock was trading at $19.56 at the beginning of the year. Since then, GERM stock has increased by 1.7% and is now trading at $19.8874. View the best growth stocks for 2024 here. How do I buy shares of Amplify Treatments, Testing and Advancements ETF? Shares of GERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amplify Treatments, Testing and Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amplify Treatments, Testing and Advancements ETF investors own include Village Farms International (VFF), Charlotte's Web (CWBHF), 3 Sixty Risk Solutions (PTVYF), Inovio Pharmaceuticals (INO), Moderna (MRNA) and PayPal (PYPL). This page (NYSEARCA:GERM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Treatments, Testing and Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Treatments, Testing and Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.